You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動|未名醫藥漲停上修業績預告半年度淨利潤預增275.24%至462.86%
格隆匯 08-19 11:51
格隆匯8月19日丨未名醫藥(002581.SZ)漲停,報6.38元,成交8063萬元,總市值42億元。

(行情來源:富途證券)
未名醫藥上週五發布2019年半年度業績預告修正公告,之前預計2019年1-6月份歸屬於上市公司股東的淨利潤比上年同期變動幅度為-526.12%至-739.36%,淨利潤變動區間為-2382萬元至-3574萬元。修正後,預計2019年1-6月歸屬於上市公司股東的淨利潤2097.60萬至3146.40萬元,同比增長275.24%至462.86%。
此次修正後的預計業績較原預計業績增加,系公司全資子公司未名生物醫藥有限公司獲得了其參股公司北京科興生物製品有限公司2019年1-6財務報表,據此計算了2019年半年度的投資收益。前次業績預告未計算北京科興生物製品有限公司2019年半年度投資收益。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account